Senseonics, Glooko to integrate data from implantable CGM

Senseonics and Glooko entered a partnership whereby data from Senseonics’ Eversense continuous glucose monitoring system will be integrated into Glooko’s mobile and web-based diabetes data management platforms, according to a press release from Senseonics Holdings.

Data from the Eversense CGM, which was approved for use in adults with diabetes by the FDA last June, can be transmitted to Senseonic’s cloud storage platform. That data will now be shared with Glooko’s management platform, allowing users and health care providers the ability to monitor historical glucose information through mobile and web-based applications.

“Glooko has a large database of millions of users who are now able to see a clearer picture of their glucose profiles by integrating Eversense CGM data,” Tim Goodnow, president and CEO of Senseonics, said in a press release. “With personalized medicine at the forefront of health care, data integration between Eversense CGM and Glooko helps provide customized data for users, as well as health care providers. We believe this information can empower our community to help manage their diabetes with new insights and actions and, ultimately, improve lives.”

Considered both the first long-term and implantable CGM, the Eversense device is implanted in the upper arm and can be used for up to 90 days before replacing. The device measures glucose levels via a fluorescence-based sensor and transmits that data every 5 minutes to a mobile application to help control hypoglycemia and hyperglycemia in adults with diabetes.

“We are excited to launch support for the breakthrough Eversense CGM on the Glooko platform,” Russ Johannesson, CEO of Glooko, said in a press release. “Eversense is an innovative solution for making glucose data more accessible, and we feel users will get tremendous value out of seeing this data correlated with food, activity and medication information they log in Glooko to help them make treatment decisions.”

Senseonics and Glooko entered a partnership whereby data from Senseonics’ Eversense continuous glucose monitoring system will be integrated into Glooko’s mobile and web-based diabetes data management platforms, according to a press release from Senseonics Holdings.

Data from the Eversense CGM, which was approved for use in adults with diabetes by the FDA last June, can be transmitted to Senseonic’s cloud storage platform. That data will now be shared with Glooko’s management platform, allowing users and health care providers the ability to monitor historical glucose information through mobile and web-based applications.

“Glooko has a large database of millions of users who are now able to see a clearer picture of their glucose profiles by integrating Eversense CGM data,” Tim Goodnow, president and CEO of Senseonics, said in a press release. “With personalized medicine at the forefront of health care, data integration between Eversense CGM and Glooko helps provide customized data for users, as well as health care providers. We believe this information can empower our community to help manage their diabetes with new insights and actions and, ultimately, improve lives.”

Considered both the first long-term and implantable CGM, the Eversense device is implanted in the upper arm and can be used for up to 90 days before replacing. The device measures glucose levels via a fluorescence-based sensor and transmits that data every 5 minutes to a mobile application to help control hypoglycemia and hyperglycemia in adults with diabetes.

“We are excited to launch support for the breakthrough Eversense CGM on the Glooko platform,” Russ Johannesson, CEO of Glooko, said in a press release. “Eversense is an innovative solution for making glucose data more accessible, and we feel users will get tremendous value out of seeing this data correlated with food, activity and medication information they log in Glooko to help them make treatment decisions.”